Anti-SSX2 (KASEKIFYV) TCR, pMSGV1(TCR-L107)
The vector of anti-SSX2 T cell receptor (TCR) is constructed for the engineering of T cell to target Human SSX2. The T cells are genetically modified through transduction with a retroviral vector expressing SSX2-specific T cell receptor. And the vector product was designed for the treatment of synovial sarcoma.
Murinized (from Human)
Synovial sarcoma, X breakpoint 2
SSX2; SSX; HD21; CT5.2; CT5.2A; HOM-MEL-40
The product of this gene belongs to the family of highly homologous synovial sarcoma X (SSX) breakpoint proteins. These proteins may function as transcriptional repressors. They are also capable of eliciting spontaneous humoral and cellular immune responses in cancer patients, and are potentially useful targets in cancer vaccine-based immunotherapy. This gene, and also the SSX1 and SSX4 family members, have been involved in t(X;18)(p11.2;q11.2) translocations that are characteristically found in all synovial sarcomas. This translocation results in the fusion of the synovial sarcoma translocation gene on chromosome 18 to one of the SSX genes on chromosome X. The encoded hybrid proteins are likely responsible for transforming activity. Alternative splicing of this gene results in multiple transcript variants. This gene also has an identical duplicate, GeneID: 727837, located about 45 kb downstream in the opposite orientation on chromosome X.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.